| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | 基于吡唑醚菌酯中间体的甲基化合成方法 | CN201610916037.8 | 2016-10-21 | CN107973751A | 2018-05-01 | 王文; 刘虎; 陈熙; 马青伟; 李舟; 王蕾; 张华 |
| 本发明公开了基于吡唑醚菌酯中间体的甲基化合成方法，将吡唑醚菌酯中间体与相转移催化剂、溶剂、碱溶液和一氯甲烷气体进行反应，控制反应温度和压力，待反应结束后，冷却降温，获得吡唑醚菌酯中间体的甲基化产物。本发明合成方法是对吡唑醚菌酯N-羟基中间体进行甲基化方法，采用一氯甲烷替代硫酸二甲酯、碳酸二甲酯、碘甲烷等作为吡唑醚菌酯生产过程中的甲基化试剂，有效降低生产成本和三废量，甲基化收率≥95.0%，HPLC外标含量≥98.0%。 | ||||||
| 22 | 供给氧化氮的前列酰胺 | CN200980127115.4 | 2009-05-11 | CN102099330B | 2014-04-30 | F·贝内迪尼; S·比翁迪; V·奇罗利; W·K·M·庄; L·董; A·H-P·克劳斯; F·尼科利; G·普拉萨纳; W·F·弗尼尔; Y·杨 |
| 本发明描述前列腺素的硝基衍生物，其具有提高的药物活性和增强的耐受性。它们可用于治疗青光眼和眼高压症。 | ||||||
| 23 | 异氰酸酯的改善的颜色稳定性 | CN200480020126.X | 2004-07-14 | CN101061067B | 2011-08-10 | 理查德·罗森; 让-迈尔·伯纳德; 沃世明; 科琳娜·瓦龙 |
| 本发明提供一种用作双组分聚氨酯涂料组合物中的组分的固化剂组合物，该固化剂组合物具有改善的颜色稳定性，其包含聚异氰酸酯、用于促进该聚异氰酸酯与活性氢化合物反应的催化剂和一种或多种抗氧化剂，所述抗氧化剂选自：第一种抗氧化剂，其包含位阻酚抗氧化剂与芳基仲胺抗氧化剂中的一种或多种；第二种抗氧化剂，其包含一种或多种有机亚磷酸酯抗氧化剂。 | ||||||
| 24 | 异氰酸酯的改善的颜色稳定性 | CN200480020126.X | 2004-07-14 | CN101061067A | 2007-10-24 | 理查德·罗森; 让-迈尔·伯纳德; 沃世明; 科琳娜·瓦龙 |
| 本发明提供一种用作双组分聚氨酯涂料组合物中的组分的固化剂组合物，该固化剂组合物具有改善的颜色稳定性，其包含聚异氰酸酯、用于促进该聚异氰酸酯与活性氢化合物反应的催化剂和一种或多种抗氧化剂，所述抗氧化剂选自：第一种抗氧化剂，其包含位阻酚抗氧化剂与芳基仲胺抗氧化剂中的一种或多种；第二种抗氧化剂，其包含一种或多种有机亚磷酸酯抗氧化剂。 | ||||||
| 25 | 聚合的N－乙酰乙酰苯胺偶氮色料 | CN01819754.X | 2001-11-26 | CN1478069A | 2004-02-25 | J·夏; M·G·梅森; J·W·米利; E·B·斯蒂芬斯; L·J·斯塔克斯; K·E·斯蒂芬森 |
| 本发明涉及色料，其包括一种含单个偶氮N－乙酰乙酰苯胺部分的生色团，其中所述的部分每一个含有至少一条聚(氧化烯)链。这种色料表现出极好的碱稳定性和耐光性，尤其是将其混合到某种介质中和/或在某些基材的表面时。这些聚(氧化烯)链使其可溶于不同的溶剂或树脂，从而使这些优秀的着色生色团能够进入各种不同的介质和/或各种不同的基材中。给出了包括这类色料的组合物和制品，以及制备本发明的色料的方法。 | ||||||
| 26 | 硫化弹性体主要是硫化橡胶脱硫用的改性剂和用该改性剂进行脱硫的方法 | CN00814369.2 | 2000-10-12 | CN1379794A | 2002-11-13 | L·贝瑞克; M·凯皮洛夫; V·戈德斯特茵 |
| 本发明提供一种用于硫化弹性体,特别是硫化橡胶,脱硫的改性剂,所说改性剂含有第一化学物质和第二化学物质,所说第一化学物质趋于分解并生成有机阳离子和胺,所说第二化学物质为第一化学物质分解的促进剂,所说促进剂含有一个构成所说胺的受体的官能团。 | ||||||
| 27 | 双氯芬酸偶联衍生物、其合成方法及抗炎作用 | CN01108030.2 | 2001-01-08 | CN1305997A | 2001-08-01 | 张奕华; 李瑞文; 季晖; 于晓琳 |
| 本发明涉及取代的呋咱和硝氧甲基苯酚通过连接基团,以酯键或酰胺键分别与双氯芬酸(DC)相偶联而成的一氧化氮供体型非甾体抗炎药(NO－DC),它们在体内释放一氧化氮,显示和临床应用的双氯芬酸钠(DC－Na)相当或增强的抗炎活性,但胃肠道副作用显著小于DC－Na,且小于专利报道的硝酸酯类NO－DC,因此具有更高的安全性和更广泛的应用。 | ||||||
| 28 | 偶氮二甲酰胺的高效制备法 | CN89101723.2 | 1989-03-22 | CN1045775A | 1990-10-03 | 陈长章; 李定 |
| AC发泡剂的高效制备法。用氯酸盐(如氯酸钠)氧化联二脲制AC发泡剂。以钒等络合物作为复合催化剂，在低酸度下，如在0.01-1N硫酸或盐酸溶液中，加入联二脲，采用反应监视仪，数字显示，监控反应过程，在搅拌下，慢慢加入氯酸钠溶液，约两小时反应完毕。反应温度控制在60-75度，反应母液可循环使用。既可稳定地得到高质量高收得率的产品，收得率达95％以上，又可节约氯酸钠的用量，几乎接近理论计算值。 | ||||||
| 29 | 폴리니트론, 및 이것의 불포화 폴리머 가교용 용도 | KR1020107012830 | 2008-12-10 | KR1020100117556A | 2010-11-03 | 치날,하칸; 리테어,헬무트 |
| 본 발명은 다기능기 니트론(선택적으로 니트론 말단의 폴리머 형태), 및 이것의 가교제 및 소광제로서의 용도 - 바람직하게는, 안정한 몰딩 화합물, 나이핑 충진제의 제조 및 이들의 잉크, 코팅제, 및 점착제에서의 사용을 위한 - 에 관한 것이다. 저온의 가교 온도에 본 발명의 특징이 있다. 다기능기 폴리니트론의 사용을 통해, 바람직하게는 촉매의 사용 없이, 모든 불포화 폴리머의 경화, 고화 및/또는 구조화가 저온에서 가능해진다. 니트론 말단의 폴리머 및/또는 저분자량의 다기능기 니트론의 사용량에 따라, 코팅 표면의 광학적 및 기계적 특성에 강한 영향을 가하는 것도 가능하다. 광학적 특성이라 함은, 무엇보다도, 코팅 시스템 및 표면 구조의 광택, 예를 들어 소광(matt) 효과를 의미한다. | ||||||
| 30 | 새로운 세포주기 조절인자 억제제 ＨＹ52, 그의 제조방법및 항암제로서의 용도 | KR1020010037116 | 2001-06-27 | KR1020030005441A | 2003-01-23 | 조율희; 임혜영; 이민아; 서수민; 김민경; 서한규; 김지홍; 임융호; 이창호; 백두진 |
| PURPOSE: A novel compound for a cell cycle regulator and a cdc2 and cdk2 protein phosphorylation enzyme inhibitor and its preparation method are provided, wherein the compound shows the anticancer activity. CONSTITUTION: The compound(HY52) is represented by the formula 1. Preferably the pharmaceutical salt of the compound is an inorganic salt comprising HCl, sulfuric acid and phosphoric acid and an organic salt comprising oxalic acid, fumaric acid, maleic acid, malic acid, citric acid, tartaric acid and glutamic acid. The preparation method comprises the steps of extracting Pata de Vaca(Bauhinia forficata) by using a solvent; filtering the extract and concentrating the filtered one; and purifying the concentrated one by chromatography. Preferably the solvent for extraction is selected from the group consisting of an alcohol; a fluorinated hydrocarbon; tetrahydrofuran, DMF, DMSO and ethyl acetate. | ||||||
| 31 | 새로운 세포주기 조절인자 억제제 ＨＹ52, 그의 제조방법및 항암제로서의 용도 | KR1020010037116 | 2001-06-27 | KR100418391B1 | 2004-02-11 | 조율희; 임혜영; 이민아; 서수민; 김민경; 서한규; 김지홍; 임융호; 이창호; 백두진 |
| PURPOSE: A novel compound for a cell cycle regulator and a cdc2 and cdk2 protein phosphorylation enzyme inhibitor and its preparation method are provided, wherein the compound shows the anticancer activity. CONSTITUTION: The compound(HY52) is represented by the formula 1. Preferably the pharmaceutical salt of the compound is an inorganic salt comprising HCl, sulfuric acid and phosphoric acid and an organic salt comprising oxalic acid, fumaric acid, maleic acid, malic acid, citric acid, tartaric acid and glutamic acid. The preparation method comprises the steps of extracting Pata de Vaca(Bauhinia forficata) by using a solvent; filtering the extract and concentrating the filtered one; and purifying the concentrated one by chromatography. Preferably the solvent for extraction is selected from the group consisting of an alcohol; a fluorinated hydrocarbon; tetrahydrofuran, DMF, DMSO and ethyl acetate. | ||||||
| 32 | [(3Ｒ,5Ｒ)/(3Ｒ,5Ｓ)]-3,5-디히드록시헥사노익산에스테르 유도체의 제조방법 | KR1020000062038 | 2000-10-20 | KR100379939B1 | 2003-04-11 | 조창우; 유호성; 조익행; 신종현 |
| PURPOSE: Provided is a method for preparing ((3R,5R)/(3R,5S))-3,5-dihydroxyhexanoic acid ester derivatives having excellent optical purity with high yield. CONSTITUTION: The method comprises stereoselectively reducing (5R/5S)-5-hydroxy-3-oxo-hexanoic acid ester derivatives represented by formula 2 by using titanium as Lewis acid, BH3-amine as a reducing agent, and amine as an additive, to form ((3R,5R)/(3R,5S))-3,5-dihydroxyhexanoic acid ester derivatives represented by formula 1. In the formulas, R1 represents a cyan group, or a hydroxy group protected by a protective group, R2 represents a C1-C4 linear or branched alkyl group, or a benzyl group. | ||||||
| 33 | 디아조늄 염 수용액의 제조 방법 | KR1020000024312 | 2000-05-08 | KR1020000077175A | 2000-12-26 | 네스틀러베른트 |
| 본발명은수용성방향족니트로화합물을수용액중에서수소화촉매하에수소로환원시켜방향족아미노화합물을수득하고, 이아미노화합물을수용액중에서디아조화시킴으로써, 유기용매를사용하지않고디아조늄염의수용액을제조하는방법에관한것이다. | ||||||
| 34 | 새로운 세포주기 조절인자 억제제 ＨＹ53, 그의 제조방법및 항암제로서의 용도 | KR1020010037117 | 2001-06-27 | KR100418392B1 | 2004-02-11 | 조율희; 임혜영; 이민아; 서수민; 김민경; 서한규; 김지홍; 임융호; 이창호; 백두진 |
| PURPOSE: Provided are HY53 as a novel inhibitor of a cell cycle control factor, and a process for producing the HY53 from Bauhinia forficata, which can be used as a cell cycle controller, a cdc2 and cdk2 protein kinase inhibitor, and an anticancer drug. CONSTITUTION: The HY53 is a compound represented by the formula 1, which has a molecular weight of 296 and a molecular formula of C17H32O2N2. And the process for producing the HY53 comprises the steps of: grinding dried leaves of the Bauhinia forficata; extracting an extract containing the HY53 from the ground Bauhinia forficata in a solvent; filtering, distilling, and condensing the extract; and refining by using a chromatography. | ||||||
| 35 | 새로운 세포주기 조절인자 억제제 ＨＹ53, 그의 제조방법및 항암제로서의 용도 | KR1020010037117 | 2001-06-27 | KR1020030010777A | 2003-02-06 | 조율희; 임혜영; 이민아; 서수민; 김민경; 서한규; 김지홍; 임융호; 이창호; 백두진 |
| PURPOSE: Provided are HY53 as a novel inhibitor of a cell cycle control factor, and a process for producing the HY53 from Bauhinia forficata, which can be used as a cell cycle controller, a cdc2 and cdk2 protein kinase inhibitor, and an anticancer drug. CONSTITUTION: The HY53 is a compound represented by the formula 1, which has a molecular weight of 296 and a molecular formula of C17H32O2N2. And the process for producing the HY53 comprises the steps of: grinding dried leaves of the Bauhinia forficata; extracting an extract containing the HY53 from the ground Bauhinia forficata in a solvent; filtering, distilling, and condensing the extract; and refining by using a chromatography. | ||||||
| 36 | [(3Ｒ,5Ｒ)/(3Ｒ,5Ｓ)]-3,5-디히드록시헥사노익산에스테르 유도체의 제조방법 | KR1020000062038 | 2000-10-20 | KR1020020031534A | 2002-05-02 | 조창우; 유호성; 조익행; 신종현 |
| PURPOSE: Provided is a method for preparing ((3R,5R)/(3R,5S))-3,5-dihydroxyhexanoic acid ester derivatives having excellent optical purity with high yield. CONSTITUTION: The method comprises stereoselectively reducing (5R/5S)-5-hydroxy-3-oxo-hexanoic acid ester derivatives represented by formula 2 by using titanium as Lewis acid, BH3-amine as a reducing agent, and amine as an additive, to form ((3R,5R)/(3R,5S))-3,5-dihydroxyhexanoic acid ester derivatives represented by formula 1. In the formulas, R1 represents a cyan group, or a hydroxy group protected by a protective group, R2 represents a C1-C4 linear or branched alkyl group, or a benzyl group. | ||||||
| 37 | Functional resin composition for controlled polymerization stress | JP2010543131 | 2009-01-14 | JP2011510002A | 2011-03-31 | オコナー，マイク; ジン，シャオミン; ハンメスファー，ポール，ディー． |
| New compositions of matter, described as photopolymerizable and photocleavable materials, are described in following formula, which contains one or more polymerizable groups within the monomer. The new compositions of matter are polymerizable by light, heat or any other suitable energy source. In addition, a hybrid reaction or polymerization is capable of being promoted simultaneously or sequentially for more effectively regulating polymerization stress or other mechanical properties due to the cleavable nature of such a novel monomer. | ||||||
| 38 | Open chain alkoxyamine and the corresponding nitroxide thereof for the controlled low temperature radical polymerization. | JP2003573037 | 2003-02-25 | JP4602671B2 | 2010-12-22 | クレーマー，アンドレアス; ネスバドバ，ペーター; ヒンターマン，トビアス; フィンク，ヨハン |
| 39 | Antioxidant nitroxide and nitrone as a therapeutic agent | JP2002576883 | 2002-04-02 | JP2004527520A | 2004-09-09 | ジェイムズ ダブリュー． ラリック，; ユクイング ワン， |
| 本発明は、以下の式：
【化１】 のうちの１つを有する新規のアダマンタン化合物を提供し、ここで、Ｒ １およびＲ ３は、Ｈ、ＯＨ、アルキル、シクロアルキル、アミノまたはアリールであり、そして、同じであっても異なっていてもよく；Ｒ ２は、Ｈ、ＮＨ ２ 、アルキル、ＯＨ、ＣＯＯＨ、アミノ、アミド、またはカルバメートであり；Ｒ４〜Ｒ８は、Ｈ、ＯＨ、ＮＨ２、アルキル、ＯＨ、ＣＯＯＨ、エステル、アミノ、アミド、またはアルキルオキシであり、そして、同じであっても異なっていてもよく；Ｒ９〜Ｒ１４は、Ｈ、アルキル、またはフェニルであり、そして、同じであっても異なっていてもよく；そしてここで、Ｒ１〜Ｒ８のいずれかがアミノである場合、この化合物は、遊離塩基およびそれらの酸付加塩である。 |
||||||
| 40 | Nitric oxide donor based on lipid | JP2002557382 | 2001-12-12 | JP2004523520A | 2004-08-05 | ナイマーク、ウェンディ; ハーマン、ロバート、エー |
| 酸化窒素を放出する新たな脂質分子を提供する。 脂質分子は、（ａ）ホスホグリセリド、（ｂ）スフィンゴシン塩基を骨格として有する脂質、（ｃ）モノアシルグリセロール、（ｄ）ジアシルグリセロール、（ｅ）グリコシルアシルグリセロール、（ｆ）Ｒを炭素原子が８個以上の分岐脂肪族鎖として、構造式（Ｉ）で表されるステロール化合物から選択された脂質分子を有し、脂質分子は、（ａ）（Ｉ）部位、（ｂ）（Ｉ）部位、（ｃ）（Ｉ）部位のいずれかを含む酸化窒素を有する官能基を含む。 更に、酸化窒素を放出する脂質分子を形成する脂質分子形成方法を提供する。 この酸化窒素を放出する脂質分子を有する様々な薬剤、局所治療用液体、薬物送達システムも開示する。 更に、酸化窒素を放出する脂質分子を用いて、患者に酸化窒素を治療的に投与する方法、様々な疾患を治療又は予防する方法、外傷の治癒を促進する方法及びアテローム病巣内に存在する細胞の数を低減する方法を開示する。 | ||||||
QQ群二维码
意见反馈
意见反馈